Bauer S et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after tumor with imatinib (INTRIGUE): A randomized, open-label, phase III trial. J Clin Oncol 2022;40(34):3918-28. Abstract
Bose S et al. A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma. ASCO 2023;Abstract 11565.
Chawla SP et al. Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol 2022;40(12):1291-300. Abstract
Chen A et al. Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS). ESMO 2023;Abstract 49MO.
Colombo C et al. A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Can Res 2022;28(18):4027-32. Abstract
D’Angelo SP et al. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma. ASCO 2023;Abstract e14531.
Eulo V, Van Tine BA. Immune checkpoint inhibitor resistance in soft tissue sarcoma. Can Drug Resist 2022;5(2):328-38. Abstract
Greene AC, Van Tine BA. Are the pieces starting to come together for management of desmoid tumors? Clin Can Res 2022;28(18):3911-3. Abstract
Grilley-Olson JE et al. A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). ASCO 2023;Abstract 11503.
Gounder M et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med 2023;388(10):898-912. Abstract
Gounder M et al. RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. ASCO 2023;Abstract 11515.
Gounder M et al. Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT). ESMO 2022;Abstract 1488MO.
Gounder M et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial. J Clin Oncol 2022;40(22):2470-90. Abstract
Gounder M et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMA|RCB1: An international, open-label, phase 2 basket study. Lancet Oncol 2020;21(11):1423-32. Abstract
Heater NK et al. The Midwest sarcoma trials partnership: Bridging academic and community networks in a collaborative approach to sarcoma. J Clin Med 2023;12(7):2561. Abstract
Jones RL et al. Avapritinib in unresectable or metastatic PDGFRA D84V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021;145:132-42. Abstract
Kasper B et al. DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). ESMO 2022;Abstract LBA2.
Kasper B et al. What clinical trials are needed for treatment of leiomyosarcoma? Curr Treat Options Oncol 2022;23(3):439-49. Abstract
Krone RJ, Van Tine BA. More data to support a cardiac-oncologic partnership. JACC CardioOncl 2023;5(1):128-30. Abstract
Larkin JR et al. Metabolomic biomarkers in blood samples identify cancers in a mixed population of patients with nonspecific symptoms. Clin Can Res 2022;28(8):1651-61. Abstract
Loong HHF et al. Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive sarcomas. CTOS 2022;Abstract 23.
Martin Broto J et al. ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma. ASCO 2023;Abstract 11502.
Miller D et al. Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer Med 2022;11(18):3471-8. Abstract
Naqash AR et al. Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS). ASCO 2021;Abstract 11519.
Osman HM, Tuncbilek M. Entrectinib: A new selective tyrosine kinase inhibitor approved for the treatment of pediatric and adult patients with NTRK fusionpositive, recurrent or advanced solid tumors. Curr Med Chem 2022;29(15):2602-16. Abstract
Reichardt P et al. Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc). ASCO 2023;Abstract 11500.
Salkeni MA et al. A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma. ASCO 2023;Abstract 11533.
Van Tine BA et al. Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. ASCO 2023;Abstract LBA11504.
Van Tine BA, Lyssiotis CA. In an era of ctDNA, is metabolomics the new kid on the block? Clin Cancer Res 2022;28(8):1477-8. Abstract
von Mehren M et al. Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study. ESMO 2021;Abstract 1540P.
Wagner A et al. Final analysis from AMPECT, an open-label phase 2 registration trial of nab-sirolimus for patients with advanced malignant perivascular epithelioid cell tumor (PEComa). CTOS 2021;Abstract 108747.
Wilky BA et al. A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas. ASCO 2023;Abstract 11501.